Newsletter Tool

Today's Rundown

Moderna, hoping to prove it's no one-trick COVID pony, posts early peek at mRNA flu shot hopeful
AHA, AMA sue Biden admin to challenge surprise billing arbitration process
Elizabeth Holmes' defense rests after 7 days of revealing testimony from the ex-Theranos CEO
Lawmakers blast pharma for 'outrageous' prices and 'anticompetitive conduct' in culmination of 3-year probe
Medtronic’s Covidien faces another Class I recall of beleaguered Puritan Bennett ventilators
Roche posts 'impressive' TIGIT combo lung cancer data, but trial deaths weigh down shares
J&J celebrates nurses with a new campaign in wake of burnout plaguing the profession
Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz: report
Senate passes bill to delay nearly 10% in Medicare cuts expected to start in January
Klick Health spreads good cheer, and $100 bills, in annual holiday video highlighting the joy of giving
Moderna taps Carnegie Mellon for in-house AI training academy
Super-fit mice reveal anti-inflammatory protein that could boost search for Alzheimer's drugs
AHA, Johns Hopkins, Athenahealth, others launch campaign to make telehealth permanent

Featured Story

Moderna, hoping to prove it's no one-trick COVID pony, posts early peek at mRNA flu shot hopeful

By Ben Adams

Moderna is set to make tens of billions of dollars this year and next from its mRNA COVID vaccine and booster, but the market won’t let the Big Biotech rest on its laurels and wants broader applicability from its programs.

AHA, AMA sue Biden admin to challenge surprise billing arbitration process

By Paige Minemyer

Rules finalized under the act have drawn significant ire from providers. They outline an arbitration model to resolve surprise billing disputes, which providers say favors health insurers in the negotiations.

Elizabeth Holmes' defense rests after 7 days of revealing testimony from the ex-Theranos CEO

By Andrea Park

The disgraced Theranos founder's legal team wrapped up the proceedings following Holmes’ more than 25 hours of questioning.

Lawmakers blast pharma for 'outrageous' prices and 'anticompetitive conduct' in culmination of 3-year probe

By Fraiser Kansteiner

The House Oversight Committee's findings mark the culmination of an almost three-year probe into the industry's pricing strategies, launched by the late Rep. Elijah Cummings in 2019. The report cites more than 1.5 million pages of internal company documents that shed light on "the decision-making of many of the world's most profitable drug companies," the committee said.

Medtronic’s Covidien faces another Class I recall of beleaguered Puritan Bennett ventilators

By Andrea Park

When it put down a casual $43 billion to merge with Covidien in 2015, Medtronic inherited its Irish partner’s Dublin headquarters and wide range of medical devices—and, consequently, any and all of their accompanying safety issues.

Roche posts 'impressive' TIGIT combo lung cancer data, but trial deaths weigh down shares

By Ben Adams

New follow-up data for Roche’s Tecentriq-tiragolumab combination therapy in certain lung cancer patients have analysts sighing in relief that the anti-TIGIT element appears to be pulling its weight.

J&J celebrates nurses with a new campaign in wake of burnout plaguing the profession

By Sharon Klahr Coey

Nurses deserve more than just a “thank you” for all they contribute, but Johnson & Johnson knows that appreciation is a good place to start. Continuing the company’s 120 year commitment to the nursing profession, J&J launched a new digital and print campaign to celebrate nurses and the work they’ve done during the pandemic and beyond.

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz: report

By Kevin Dunleavy

Novartis CEO Vas Narashimhan confirmed buyer interest in a purchase of the company's generics unit Sandoz. Last month Swedish investment group EQT and the billionaire Struengmann brothers of Germany were said to be considering a purchase for $21.6 billion.

Senate passes bill to delay nearly 10% in Medicare cuts expected to start in January

By Robert King

The Senate passed a bill late Thursday that delays nearly 10% in cuts to Medicare set to start in January, as provider groups hope lawmakers now work on a more permanent fix.

Klick Health spreads good cheer, and $100 bills, in annual holiday video highlighting the joy of giving

By Natalie Missakian

Klick Health's annual holiday video started as a thank-you to clients but grew into a beloved tradition—and unwitting recruiting tool. This year, it mailed employees each a $100 bill and asked them to use it however they wished to spread joy.

Moderna taps Carnegie Mellon for in-house AI training academy

By Conor Hale

As it looks to one day move beyond COVID-19 vaccines and take its mRNA tech to other diseases, Moderna has established a new artificial intelligence training program for its employees in partnership with Carnegie Mellon University. The company’s AI Academy represents a “broader investment in a digital-first culture,” with curriculums designed for working professionals.

Super-fit mice reveal anti-inflammatory protein that could boost search for Alzheimer's drugs

By Arlene Weintraub

A Stanford team discovered that a protein called clusterin is prevalent in exercising mice and prompts anti-inflammatory, brain-boosting effects. They concluded that a drug that reduces inflammation in the brain by mimicking the binding of clusterin to endothelial cells could prove effective in Alzheimer’s and other diseases.

AHA, Johns Hopkins, Athenahealth, others launch campaign to make telehealth permanent

By Anastassia Gliadkovskaya

Telehealth access is under threat as the temporary lift on the usual restrictions is set to end in January, several organizations say. The public health emergency order that allows for the exemption was already renewed six times by the Department of Health and Human Services.

PM Tracker